TG Therapeutics (TGTX) Misses Q2 EPS by 4c

TG Therapeutics (NASDAQ: TGTX) reported Q2 EPS of ($0.33), $0.04 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $30.1 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Ennis (EBF) Reports In-Line Q1 EPS
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance